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Extracorporeal shock wave therapy has been reported as an effective treatment for lower limb ulceration. The aim
of this systematic review was to investigate the effectiveness of extracorporeal shock wave therapy for the
treatment of lower limb ulceration.
Five electronic databases (Ovid MEDLINE, CINAHL, Web of Knowledge, Scopus and Ovid AMED) and reference lists
from relevant studies were searched in December 2013. All study designs, with the exception of case-reports, were
eligible for inclusion in this review. Assessment of each study’s methodological quality was performed using the
Quality Index tool. The effectiveness of studies was measured by calculating effect sizes (Cohen’s d) from means
and standard deviations.
Five studies, including; three randomised controlled trials, one quasi-experimental study and one case-series design
met our inclusion criteria and were reviewed. Quality assessment scores ranged from 38 to 63% (mean 53%).
Improvements in wound healing were identified in these studies following extracorporeal shock wave therapy.
The majority of wounds assessed were associated with diabetes and the effectiveness of ESWT as an addition to
standard care has only been assessed in one randomised controlled trial.
Considering the limited evidence identified, further research is needed to support the use of extracorporeal shock
wave therapy in the treatment of lower limb ulceration.Introduction
Lower limb ulceration is reported as a common problem
world-wide, and is considered a major social and eco-
nomic burden [1]. Lower limb ulceration is associated
with numerous comorbidities including, but not limited
to; diabetes, peripheral vascular disease and venous
insufficiency [2]. The management of ulceration is
dependent on the proposed causes, although common
interventions may include both non-surgical and surgical
approaches [3]. Typically, effective ulcer management in-
volves local wound care, compression therapy, pressure
redistribution, infection management and optimization
of vascular status [2,4,5]. Recently, extracorporeal shock* Correspondence: paul.butterworth@scu.edu.au
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unless otherwise stated.wave therapy, for the treatment of chronic ulceration,
has also gained attention in the literature [6].
The use of extracorporeal shock waves in medicine
was first reported over 30 years ago as a treatment for
kidney stones [7], and is commonly referred to as ‘extra-
corporeal shock wave lithotripsy’, or ‘ESWL’ [8]. Extra-
corporeal shock waves are also used as a treatment for
musculoskeletal conditions such as plantar heel pain
[9,10] and boney non-union [11,12], and is commonly
referred to as ‘extracorporeal shock wave therapy’ (ESWT)
to differentiate from ESWL [13]. Furthermore, the use of
ESWT has also been reported in the treatment of arterial
aneurysms [14] and intermittent claudication [15,16]. Al-
though the mechanisms by which ESWT improves ulcer
healing are not fully understood, it is purported to stimu-
late vascular in-growth, neovascularization and cell prolif-
eration [17,18], therefore improving healing rates in
chronic ulcers [1]. Typically, ESWT would entail one tontral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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healing.
Despite the reported success of ESWT for the treat-
ment of lower limb ulceration, the quality of evidence
investigating the effectiveness of this intervention has
not been reviewed in detail. Therefore, the aim of this
review was to investigate the effectiveness of ESWT for
the treatment of lower limb ulceration.
Review
Types of studies included
All studies included in this review were obtained from
English-language peer reviewed scientific journals inves-
tigating the effectiveness of ESWT for lower limb ulcer-
ation. All study designs, with the exception of case-
reports, were eligible for inclusion in this review. Letters
to the editor, opinion pieces and editorials were also
excluded.
Types of participants included
Studies were included if the use of ESWT for the
treatment of lower limb ulceration was assessed. The
category of ulcers included in this review were those of
neurovascular origin (i.e. diabetic, neuropathic, neuro-
vascular or vascular). Studies where the participant’s
ulcer was associated with pressure sores, burns or surgi-
cal complications were excluded.
Search strategy for identification of studies
In December 2013 an electronic database search was
conducted using Medical Subject Headings (MeSH),
followed by a keyword search strategy. Auto-alerts were
developed to provide updates on recent publications
until the review was finalised (March 2014). The follow-
ing databases were searched: Ovid MEDLINE (1966 to
date), CINAHL (1982 to date), Web of Knowledge,
Scopus and Ovid AMED (from inception). The database
search strategy is presented in Table 1.
Upon completion of the search (March 2014), a hand
search was performed of references from the studies iden-
tified in the electronic search, and Google Scholar was
searched in an attempt to identify any further material.Table 1 Database search strategy
Subject term
keywords
1. Exp. Extra corporeal shock wave therapy
2. “Extra corporeal shock wave therapy” or ESWT or
“shock wave therapy” or lithotripsy




5. Lower limb or foot* or leg or arterial or venous or
neuropathic or diabet*
6. 4 or 5
Combine 10. 3 and 6Two reviewers (PAB and TPW) then independently
reviewed titles and abstracts according to the pre-
determined inclusion criteria. Discrepancies between re-
viewers regarding eligibility were discussed until consen-
sus was reached. Progression to full text review was then
permitted.
Data extraction and analysis
A predefined data extraction form was used in the
extraction process (Additional file 1). Relevant data
(means, mean differences, standard deviations and p
values) were extracted from studies by two investigators
(PAB and TPW), with specific attention to the following
variables; study design, participant numbers, mean age,
sex, ulcer classification, change in healing and ulcer size
and ESWT protocol used. The data pertaining to each
study was then assigned a numerical value to ensure the
two investigators (PAB and TPW) were blinded to au-
thor and publication details during quality assessment.
Where disagreements occurred during the quality as-
sessment process, a third assessor (YDP) made the final
decision on quality assessment scores. Where studies
provided sufficient statistical data, effect size (Cohen’s d)
was calculated from means and standard deviations.
Effect sizes were categorized as follows: negligible effect
(≥ − 0.15 and <0.15); small effect (≥0.15 and <0.40);
medium effect (≥0.40 and <0.75); large effect (≥0.75
and <1.10); very large effect (≥1.10 and <1.45) and, huge
effect (≥1.45) [19,20].
Assessment of methodological quality
Assessment of each study’s methodological quality was per-
formed using the Quality Index tool developed by Downs
and Black [21]. This tool has been shown to have high in-
ternal consistency (KR-20 = 0.89), good test-retest reliabil-
ity (r = 0.88) and good inter-rater reliability (r = 0.75). The
Quality Index tool consists of 27 items, and allows for
assessment of internal and external validity, reporting and
power.
For this systematic review, an a priori decision was
made to remove two items where they did not apply to
the respective studies identified. Firstly, Item 25 was re-
moved for non-randomised controlled studies, as it has
been shown that case mix adjustment cannot reduce the
extent of bias in non-randomised trials [22]. Secondly,
Item 27 was removed for all studies, as a minimally im-
portant difference has not been established for measuring
the outcomes of ESWT in the treatment of ulceration.
We chose to present the quality assessment results as
percentage scores, which is typical of previous studies
using the Quality Index tool [20,23-24]. Furthermore,
after obtaining data from the included studies, the
findings were combined using a narrative rather than a
quantitative approach, owing to study heterogeneity.
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A total of 555 results were identified through our elec-
tronic search (Additional file 2) and one further study
from other sources (i.e. as laid out in our search strat-
egy). Upon the removal of duplicates, 123 studies were
suitable for initial review. Following the review of titles
and abstracts, 25 studies were extracted for full review
and finally, five studies were considered appropriate for
inclusion (Additional file 3). The reasons for the exclu-
sion of studies are available in Additional file 4. A flow
diagram, as described by Moher and colleagues [25], is
presented in Figure 1, highlighting the study selection
process.
Quality of the evidence
The inter-rater reliability of the Quality Index scores
was not calculated due to the small number of trials in-
cluded in the review [23]. However, perfect agreement
was recorded on all items except item 5 (50% agree-
ment) and item 13 (65% agreement). Table 2 indicates
that moderate study quality was identified across trials
(quality assessment scores ranged from 38 to 63%, mean
53%). External validity across studies was rated most
poorly, due to deficient definitions of the source popula-
tion and methods of patient selection, and poor identifi-
cation of confounding factors. Studies also rated poorly















Figure 1 Study selection process.Trial characteristics
There were three randomised control trials, one quasi-
experimental study and one case-series study identified,
the characteristics of which are presented in Table 3.
Moretti et al. [26] conducted a randomised controlled
study in participants with neuropathic diabetic foot ul-
cers, to evaluate standard care and ESWT (intervention
group) against standard care alone (control group). Both
groups received standard care consisting of therapeutic
footwear, debridement and dressings, although none of
these variables were described in detail. Furthermore, the
treatment of infection was undertaken where necessary
and was not considered as a reason to exclude participants.
Saggini et al. [27] conducted a quasi-experimental
study and investigated 40 participants with chronic post-
traumatic, venous and diabetic ulcers (17 venous ulcers,
7 diabetic). The case group (n = 30) received ESWT;
between ESWT treatment sessions, the participants con-
tinued previous conservative treatment, although it is
unclear what this treatment consisted of. There were 10
control participants who received regular conservative
dressings, although the authors did not explain what
conservative care involved.
Wang et al. [28] compared ESWT with hyperbaric
oxygen therapy (HBO) in chronic diabetic foot ulcers.
Seventy-four participants were randomly divided into
two groups according to the dates that they wereitional records identified 
hrough other sources 
(n = 1)
s removed 










Table 2 Quality assessment scores from the Quality index tool [21]
Quality index items Moretti [26] Saggini [27] Wang [28] Wang [29] Schaden [17]
Reporting
1. Study hypotheses/aim/objective 1 0 1 1 1
2. Main outcomes 1 1 1 1 1
3. Participant characteristics 1 1 1 1 1
4. Interventions of interest 1 0 1 1 1
5. Distribution of principal confounders 1 1 0 1 1
6. Main findings 1 1 1 1 1
7. Estimates of random variability 1 0 1 0 1
8. Adverse events described 0 1 0 1 1
9. Participants lost to follow up described 1 0 1 1 1
10. Actual probability values reported 0 0 0 1 1
External validity
11. Were subjects asked to participate representative of population from which
they were recruited?
0 0 0 0 0
12. Were subjects prepared to participate representative of the entire
population from which they were recruited?
0 0 0 0 0
13. Were the staff, places and facilities where the patients were treated,
representative of the treatment patients received?
1 1 0 1 1
Internal validity (bias)
14. Was an attempt made to blind study subjects to the intervention they
have received?
0 0 0 0 0
15. Was an attempt made to blind those measuring the main outcomes of the
intervention?
0 0 0 0 0
16. If any of the results of the study were based on ‘data dredging’ was this
made clear?
1 1 1 0 1
17. Does analysis adjust for lengths of follow up or is the time period between
intervention and outcome the same?
0 0 0 0 0
18. Were the statistical tests used to assess the main outcomes appropriate? 0 1 0 1 1
19. Was compliance with the intervention reliable? 1 1 1 1 1
20. Were the main outcome measures used accurate (valid and reliable)? 1 0 1 1 0
Internal validity (selection bias)
21. Were cases and controls recruited from the same population? 0 0 1 1 0
22. Were cases and controls recruited over the same period of time? 1 1 1 0 1
23. Were study subjects randomised to intervention groups? 1 0 1 1 0
24. Was randomised intervention assignment concealed from participants/
researchers until recruitment complete?
0 0 0 0 0
25. Was there adequate adjustment for confounding in the analysis from
which the main findings were drawn?
0 * 0 0 1
26. Were losses to follow up of patients taken into account? 1 0 1 1 1
Power
27. Did the study have sufficient power to detect a clinically important effect? * * * * *
Total score% 55 38 52 59 63
Notes:
All questions were scored on the following scale: yes = 1, unable to determine = 0, no = 0.
Question 5 is an exception with scores allocated: yes = 2, partially = 1, no = 0.
*Item removed.
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Table 3 Characteristics of included studies
Primary
author







Mean duration of disease
in months (SD)
Ulcer classification ESWT protocol
Moretti [26] Rate of re-
epithelialization
RCT (a) 15 56.2 ± 4.9 40 UD Neuropathic (diabetic) plantar
foot ulceration≥6 months
duration; area >1 cm2 and
diameter between 0.5 and 5 cm
3 sessions (every 72 hours); 100
pulses per 1 cm2; EFD 0.03 mJ/mm2
15 56.8 ± 7.5 53 UD
Saggini [27] Exudate, Quasi-
experimental
(a) 30 58.5 43 5.3 Venous ulcers; diabetic ulcers;
unresponsive to conservative
care for≥3 months duration
4 to 10 sessions; 100 impulses
per 1 cm2; EFD 0.037 mJ/mm2;
frequency of 4 Hz or 240
impulses/min
Granulation and 10 66.6 40 5.2
Fibrin/necrotic tissue
Wang [28] Healing rates RCT (a) 34 58.6 ± 12.6 UD 22.7 ± 20.9 Diabetic foot ulcer >3 months
duration
3 treatments; repeat course
performed in cases with
incomplete healing; 300 plus




(a) 36 63.4 ± 10.3 UD 19.0 ± 19.5
Wang [29] Healing rates RCT (a) 39 60.5 ± 14.0 UD 6* (3 to16) Diabetic foot ulcer >3 months
duration
6 treatments; Ulcer size dependent
treatment; minimum 500 pulses;
EFD 0.27 mJ/cm2Histopathological
analysis
(a) 38 62.5 ± 14.0 UD 6* (6 to10)
Schaden [17] Safety and feasibility
of ESWT
Case-series (a) 31 61.0 48 UD Complicated, non-healing,
acute and chronic venous and
arterial ulcers
Mean sessions 1.9 to 3.7;
100 impulses per 1 cm2;
EFD 0.1 mJ/mm2
Notes:
EFD: energy flux density; RCT: randomised controlled trial.
SD: standard deviation; UD: unable to determine.
*Median value (range) reported.
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ulcers received ESWT, whereas 38 participants with 38
ulcers received HBO therapy. A repeat course of ESWT
was performed in cases with incomplete healing from
the first course of treatment. Participants resumed the
same wound care technique at home after treatment in-
cluding offloading on the affected leg, wound cleansing
with sterile normal saline solution, and application of
silver sulfadiazine cream. Participants in the HBO group
received the same wound care as the ESWT group. In
their second study comparing ESWT with HBO therapy
in chronic diabetic foot ulcers, Wang et al. [29] ran-
domly divided participants according to computer gener-
ated block labels. Forty-three participants were assigned
to the ESWT group and 45 participants were assigned to
the HBO group. After ESWT, participants resumed their
initial wound care protocol including offloading on the
affected foot, wound cleansing with sterile normal saline
solution and application of silver sulfadiazine cream.
Participants in the HBO group received the same wound
care protocol after treatment as the ESWT group.
In a study by Schaden et al. [17], the safety and feasibility
of ESWT was assessed in 208 participants with a variety of
wounds that included 31 ulcers of a neurovascular origin.
The intervention applied to all participants was a combin-
ation of debridement, ESWTand moist wound dressings.
Evidence for the effectiveness of ESWT in the treatment
of lower limb ulceration
Table 4 provides a description of the mean differences of
ulcer healing between groups. Moretti et al. [26] found
that after 20 weeks of treatment, 53.33% of the ESWTTable 4 Mean differences in ulcer healing between groups of
Primary
author
Difference between groups Contro
ESWT
Moretti [26] Wound closure: 53.33% 33.33%
healing time: 60.8 days (SD 4.7 days) 82.2 day
Saggini [27] UD UD
Wang [28] 31% completely healed 22% co
58% improved 50% im
11% remained unchanged. 28% rem
≥50% improved in 89% of participants ≥50% im
Wang [29] Completely healed 57% Comple
≥50% improved in 32% of participants ≥50% im
unchanged ulcers in 11% unchan
Schaden [17] NA NA
Notes:
UD: unable to determine; NA: not applicable.
ESWT = extracorporeal shock wave therapy.
SD = standard deviation.
Cohen’s d: negligible effect (≥ − 0.15 and <0.15), small effect (≥0.15 and <0.40), med
(≥1.10 and <1.45), huge effect (≥1.45).group had complete wound closure compared with
33.33% of the control group, and healing times were
60.8 and 82.2 days respectively (p < 0.001).
Saggini et al. [27] treated 32 ulcers with ESWT and
reported that 16 ulcers healed completely within six ses-
sions of ESWT. In those ulcers that did not completely
heal, statistical significance (p < 0.01) was reported with
regard to decrease in ulcer size, after four to six sessions
of ESWT. There was no evidence in this study of a dif-
ference between the two groups regarding ulcer healing
or change in ulcer size.
Wang et al. [28] found that in the ESWT group, 31%
of ulcers completely healed, 58% improved and 11%
remained unchanged. In the HBO group 22% completely
healed, 50% improved, and 28% remained unchanged.
These differences were significant at p = 0.001. Further-
more, greater than 50% improvement of the ulcer was
observed in 89% of participants in the ESWT group and
72% of participants in the HBO group (p < 0.001). In
their second study comparing ESWT and HBO, Wang
et al. [29] found: completely healed ulcers in 57% and
25% (p = 0.003); ≥ 50% improved ulcers in 32% and 15%
(p = 0.071), and unchanged ulcers in 11% and 60%
(p < 0.001) respectively.
Schaden et al. [17] found that venous stasis ulcers dem-
onstrated the worst healing rates (36% versus 66% for all
other ulcers, p = 0.001). Furthermore, arterial insufficiency
ulcers did not completely heal in 33% of cases, the second
worst healing rate of all ulcer types. The primary outcome
assessed in their study was the safety and feasibility of
using ESWT on wounds, the authors concluding that
ESWT is a safe and effective treatment.included studies
l p value Effect size
(Cohen’s d)
< 0.001 UD
s (SD 4.7 days) <0.001 4.43, Huge effect
UD UD
mpletely healed <0.001 UD
proved <0.001 UD
ained unchanged <0.001 UD
proved in 72% of participants <0.001 UD
tely healed 25% =0.003 UD
proved in 15% of participants =0.071 UD
ged ulcers in 60% <0.001 UD
NA NA
ium effect (≥0.40 and <0.75), large effect (≥0.75 and <1.10), very large effect
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The aim of this systematic review was to investigate the
effectiveness of ESWT for the treatment of lower limb
ulcers. We evaluated five studies in this review, and
identified a trend to suggest that ESWT may be effective
in improving wound healing and decreasing wound size.
Furthermore, ESWT may also be a safe treatment option
with few complications associated with its use, however;
we found average study quality for the studies identified.
External validity across studies was rated most poorly,
due to deficient definitions of the source population and
methods of patient selection, and poor identification of
confounding factors. It is difficult therefore, to generalise
the findings of the studies to the populations from which
the study participants were derived. Furthermore, it
is unknown whether participants were representative of
the population from which they were recruited. As such,
all five studies performed poorly on the external validity
questions, scoring a mean of only 27% for questions 11
to 13 on the quality Index tool.
All studies also rated poorly on the internal validity
component of the Quality Index (questions 14 to 26).
For example, Moretti et al. [26] conducted a randomised
controlled study in participants with neuropathic dia-
betic foot ulcers, to evaluate standard care and ESWT
(intervention group) against standard care alone (control
group). While it is unclear what standard care comprised
of in both groups, it appears that both groups received
therapeutic footwear, debridement and dressings, and
treatment of infection where present. Subsequently,
treatment effects in the intervention group could have
been influenced by the variation in the standard care
regime, especially where antibiotics were used to treat
infection. In the study by Saggini et al. [27], the authors
described the control group as receiving usual conserva-
tive dressings but did not clearly describe the standard
care received by the intervention group. The lack of
standardization is of particular concern considering the
non-blinded design of the studies. Therefore, the conclu-
sions made by the authors of these studies should be
considered in light of these methodological flaws.
The internal validity of the studies identified may also
have been threatened due to a loss of participants during
the study. While Moretti et al. [26] and Saggini et al.
[27] suggested that all participants in their study com-
pleted the respective trials; Wang et al. [28] described a
loss of four participants during their study, with no ref-
erence to how these losses were accounted for in their
final analysis. In their second study, Wang et al. [29] de-
scribed a loss of 11 participants during their trial, again
with no discussion or statistical analysis to account for
this loss. As there was no reference to an intention-to-
treat analysis in the studies by Wang et al. [28,29], group
characteristics may have changed during the trial,resulting in over-estimation of the treatment effect; only
the study by Schaden et al. [17] made an attempt to
adjust their statistical analysis with intention-to-treat
analysis. Further threats to internal validity might have
occurred as no attempt was made to blind those respon-
sible for measuring the outcomes in any of the five
studies. Furthermore, the details of randomization in the
study by Moretti et al. [26] were not made clear in their
study. Consequently, differences in baseline characteris-
tics may have influenced the effects of the intervention.
The classification of ulceration varied across the five
studies identified in this review. Moretti et al. [26] de-
fined their inclusion of neuropathic diabetic foot ulcer-
ation as occuring below the malleoli for a period of at
least 6 months with an area wider than 1 cm2. Although
Moretti et al. [26] made an attempt to define peripheral
neuropathy and standard care, ulcer classification and
measurement of change in ulcer size was not undertaken
using a recognised or validated measure. Saggini et al.
[27] included venous and diabetic ulcers in those partici-
pants with a history of chronic ulcers for more than
three months. While Saggini et al. [27] defined a recog-
nised measure of wound exudate, the measurement of
change in ulcer size was not appropriately described in
their methods. The two studies by Wang et al. [28,29]
included participants with recurrent chronic diabetic ul-
cers of the foot for more than three months duration. In
these two studies [28,29], and in the study by Schaden
et al. [17], there was no description of a recognised method
used to determine the change in ulcer size following the
intervention. Consequently, the variation in ulcer classifica-
tion and the poor definitions of change in ulcer size used
across studies renders these results susceptible to bias.
The ESWT protocol varied between studies resulting
in study heterogeneity, making comparison difficult.
Specifically, there were differences in the duration, fre-
quency and strength of ESWT application identified be-
tween studies. Furthermore, these differences were also
noticeable within studies. For example, a repeat course
of treatment was performed in cases with incomplete
healing from the first course of treatment in the study
by Wang et al. [28]. Moreover, the ESWT treatment
dosage for each participant in the studies by Wang et al.
[29] and Schaden et al. [17] was dependent on the size
of the participant’s ulcer, rather than a pre-determined
intervention dose. In the study by Saggini et al. [26],
participants’ received anywhere between four and 10
sessions of ESWT; essentially, in these three studies, the
likelihood of the results being due to the actual interven-
tion cannot be determined.
This systematic review has identified a number of im-
portant implications for future research. Firstly, to reduce
bias it is essential that when evaluating the effectiveness of
ESWT for the treatment of lower limb ulceration, that
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used [30,31]. Second, it is necessary that outcome mea-
sures used are reliable and valid and include both specific
and generic measures [32]. This should also include
detailed information about the criteria used to identify the
presence of lower limb ulceration as there is substantial
variability in the criteria used. Third, acknowledgement
and adjustment for confounding variables should be
included in future trials and if necessary, stratification of
analyses should be made on the basis of the type of ulcer-
ation. This will ensure that such trials include sufficient
information for the methods to be critiqued and allow
comparisons to be made with similar investigations.
Finally, the establishment of an optimal ESWT regimen
remains to be established and should be the focus of
future research.
The existing evidence that supports the use of ESWT
for treatment of lower limb ulceration therefore needs to
be viewed in light of some limitations. Firstly, there were
only two studies (one of which was an RCT) that investi-
gated the effect of ESWT versus standard treatment, and
there were small participant numbers in the studies
identified. Secondly, this review identified significant
methodological heterogeneity between studies. For ex-
ample; one of the studies in this review included smokers
and also assessed ulceration associated with multiple co-
morbidities [27], whereas the other three studies did not.
Third, the outcome measures assessed across studies was
inconsistent; although all studies assessed the change in
ulcer size or ulcer healing rates as their primary outcome,
the definitions used to determine these changes varied be-
tween studies. There were some limitations to our review
design; there was no pooling of data for meta-analysis and
no statistical measure of heterogeneity performed. There
were however, two strengths of this review; the use of a
validated quality assessment tool [20], and the systematic
approach used.
Conclusions
This systematic review identified five studies that reported
on the effectiveness of ESWT for the treatment of lower
limb ulcers. There is limited evidence to support ESWTas
a treatment for lower limb ulceration. Considering this,
further research is needed to support the use of ESWT in
the treatment of lower limb ulceration.
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